Prognostic significance of serum p53 protein and p53 antibody in patients with surgical treatment for head and neck squamous cell carcinoma

被引:39
作者
Chow, V
Yuen, APW
Lam, KY
Ho, WK
Wei, WI
机构
[1] Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2001年 / 23卷 / 04期
关键词
ELISA; immunohistochemistry; cancer; metastasis;
D O I
10.1002/hed.1032
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Objectives. This study aims at investigating the prognostic values of serum p53 protein and anti-p53 antibody in patients undergoing surgical treatment for head and neck squamous cell carcinoma (HNSCC). Methods. Serum p53 protein and anti-p53 antibody concentrations were determined by an enzyme-linked immunosorbent assay (ELISA) in 75 patients with HNSCC and 28 healthy controls. In 28 patients, formalin-fixed tumor tissues were also available for immunohistochemical staining by an anti-p53 DO7 monoclonal antibody. The results were correlated with the clinico-pathologic parameters. Results. The mean preoperative serum concentration of p53 protein in patients with HNSCc was significantly higher than healthy controls (59.45 pg/mL vs 16.4 pg/mL, p = .007). Preoperative serum p53 antibody was present in 23 (31%) patients and was present in one healthy control. Eighteen (62%) tumor tissues showed p53 overexpression by immunohistochemistry. The presence of serum anti-p53 antibody before operation was associated with a significantly higher incidence (65%) or nodal metastasis compared with 27% nodal metastasis in patients with absence of serum anti-p53 antibody (p = .002). Conclusion. Preoperative serum p53 antibody was a significant prognostic factor for nodal metastasis of HNSCC. (C) 2001 John Wiley & Sons, Inc.
引用
收藏
页码:286 / 291
页数:6
相关论文
共 27 条
[1]  
AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217
[2]   Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma [J].
Bourhis, J ;
Lubin, R ;
Roche, B ;
Koscielny, S ;
Bosq, J ;
Dubois, I ;
Talbot, M ;
Marandas, P ;
Schwaab, G ;
Wibault, P ;
Luboinski, B ;
Eschwege, F ;
Soussi, T .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (17) :1228-1233
[3]  
COUGH MJ, 1994, HEAD NECK-J SCI SPEC, V16, P495
[4]  
FRANK JL, 1994, CANCER-AM CANCER SOC, V73, P181, DOI 10.1002/1097-0142(19940101)73:1<181::AID-CNCR2820730131>3.0.CO
[5]  
2-3
[6]  
Gadducci A, 1998, ANTICANCER RES, V18, P3763
[7]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53
[8]  
LABRECQUE S, 1993, CANCER RES, V53, P3468
[9]   Implications of p53 alterations and anti-p53 antibody response in head and neck squamous cell carcinomas [J].
Lavieille, JP ;
Righini, C ;
Reyt, E ;
Brambilla, C ;
Riva, C .
ORAL ONCOLOGY, 1998, 34 (02) :84-92
[10]   TUMOR ANGIOGENESIS, THE P53 ANTIGEN, AND CERVICAL METASTASIS IN SQUAMOUS-CELL CARCINOMA OF THE TONGUE [J].
LEEDY, DA ;
TRUNE, DR ;
KRONZ, JD ;
WEIDNER, N ;
COHEN, JI .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1994, 111 (04) :417-422